Immunohistochemical analysis of apocrine breast lesions - Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ
Immunohistochemical analysis of apocrine breast lesions - Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ
复制标题
DOI：
10.1016/s0344-0338(97)80053-2
复制
发表时间：
1997-01-01
影响因子：
2.8
通讯作者：
Gatalica, Z
中科院分区：
文献类型：
--
作者：
Gatalica, Z
从良性上皮化生到大汗腺癌，在一系列乳腺上皮病变中观察到大汗腺表型。顶浆腺化生是女性乳房纤维囊性变的常见表现。原位和浸润性大汗腺癌是导管癌的罕见变体。本文应用免疫组化方法对10例乳腺大汗腺化生、3例原位大汗腺癌和10例浸润性大汗腺癌进行了雄激素受体（雌激素、孕激素、雄激素）、p53、bcl-2和BRST-2的检测。石蜡包埋组织和抗生物素蛋白-生物素过氧化物酶复合物系统，雄激素受体（AR）的表达一致增加，在所有的情况下，顶浆腺化生时，与周围正常，非顶浆腺乳腺上皮细胞相比。这种雄激素受体的过度表达伴随着免疫可检测的雌激素和孕激素受体的丢失，以及bcl-2的丢失。在原位大汗腺癌中观察到相同的免疫反应性模式，但在侵袭性大汗腺癌中观察到的频率较低，其仅偶尔表达AR作为唯一的类固醇激素受体。
Apocrine phenotype is observed in a spectrum of breast epithelial lesions spanning from benign metaplasias to apocrine carcinoma. Apocrine metaplasia is a common finding in fibrocystic change of the female breast. In situ and invasive apocrine carcinomas are rare variants of ductal carcinoma. All breast apocrine lesions were shown to be associated with increased androgen hormones metabolism.We have evaluated 10 cases of apocrine metaplasia, 3 cases of in situ apocrine carcinoma and 10 cases of invasive apocrine carcinomas using immunostaining method for steroid hormone receptors (estrogen, progesterone, androgen), p53, bcl-2 and BRST-2. Paraffin embedded tissue and avidin-biotin peroxidase complex system were used.Androgen receptor (AR) expression is consistently increased in all cases of apocrine metaplasia when compared with surrounding normal, non-apocrine breast epithelium. This androgen receptor over-expression is accompanied by the loss of immuno-detectable estrogen and progesterone receptor, and also the loss of bcl-2. An identical pattern of immuno-reactivity is seen in in situ apocrine carcinomas, but it is observed with less frequency in invasive apocrine carcinomas, which only infrequently express AR as the only steroid hormone receptor.